nach oben

Erschienen in:

01.07.2022 | News item

Duvelisib increases risk of serious AEs and death

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

The USA FDA is warning that 5-year survival results of the phase III DUO trial have shown that duvelisib [Copiktra] appears to increase the risk of death compared with the monoclonal antibody ofatumumab in patients with small lymphatic lymphoma or chronic lymphocytic leukaemia. The trial also found that duvelisib increased the risk of serious adverse events (AEs) including infections, diarrhoea, inflammatory bowel disease, pneumonitis, skin disorders and elevated liver enzymes. …

FDA warns about possible increased risk of death and serious side effects with cancer drug Copiktra (duvelisib) Internet Document : 6 Jul 2022. Available from: URL: https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-possible-increased-risk-death-and-serious-side-effects-cancer-drug-copiktra

Titel: Duvelisib increases risk of serious AEs and death
Publikationsdatum: 01.07.2022
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-022-19032-9

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Duvelisib increases risk of serious AEs and death

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2022

Influenza-virus-vaccine

Esomeprazole

Immunosuppressants/rituximab

Atezolizumab

Ramipril overdose

Cytarabine/inotuzumab-ozogamicin/nelarabine